7 completed, 3 terminated, 1 active not recruiting, 1 not yet recruiting. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 7, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow COPD Exacerbation: new trials by email Literature Review of COPD Exacerbation trials Research Report on COPD Exacerbation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD) Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation | Phase 4 | Not yet recruiting | University of Tennessee Graduate School of Medicine | 280 | 2026-11-12 | 2026-10-19 |
| Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Titrated Oxygen, Standard Oxygen - COPD Exacerbation, COPD Exacerbation Acute | Phase 4 | Recruiting | Central Denmark Region | 1888 | 2025-06-02 | 2026-10-02 |
| Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause Long acting muscarinic antagonists (LAMAs) in the evening - COPD Exacerbation | Phase 4 | Completed | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 10011 | 2023-01-27 | 2025-02-19 |
| Atorvastatin Effect on Reduction of COPD Exacerbations Atorvastatin 40 Mg Oral Tablet, Placebo - Copd, COPD Exacerbation | Phase 4 | Active not recruiting | Medical University of Bialystok | 460 | 2022-02-11 | 2026-04-21 |
| Eosinophil-guided Reduction of Inhaled Corticosteroids Azithromycin, ICS - COPD, Inhaled Corticosteroid | Phase 4 | Completed | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 444 | 2021-06-28 | 2026-01-28 |
| Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation - COPD Exacerbation | Phase 4 | Unknown | PARZIBUT Gilles | 200 | 2021-02-15 | 2021-02-04 |
| Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation | Phase 4 | Completed | University of Tennessee Graduate School of Medicine | 60 | 2020-12-09 | 2026-08-03 |
| The Effects of Enoximone in Acute Exacerbation COPD Enoximone - COPD Exacerbation, Enoximone | Phase 4 | Terminated | Rijnstate Hospital | 3 | 2020-05-12 | 2022-01-13 |
| Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation Oxygen gas - COPD Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation | Phase 4 | Terminated | Esbjerg Hospital - University Hospital of Southern Denmark | 23 | 2020-02-03 | 2026-03-11 |
| Stratified TreAtment to Reduce Risk in COPD Prednisolone - COPD Exacerbation | Phase 4 | Completed | University of Oxford | 203 | 2017-11-02 | 2020-07-21 |
| Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) Nebulizers, Dry Powder Inhaler, Brovana - COPD, COPD Exacerbation | Phase 4 | Terminated | Wake Forest University Health Sciences | 40 | 2017-10-03 | 2021-06-22 |
| Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB) ceftidoren, levofloxacin - COPD Exacerbation | Phase 4 | Completed | University of Milan | 40 | 2012-01-01 | 2012-06-05 |
| Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Roflumilast, Placebo - COPD, COPD Exacerbation | Phase 4 | Completed | AstraZeneca | 2354 | 2011-09-30 | 2017-04-13 |
| Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day - COPD Exacerbation | Phase 4 | Completed | Fadoi Foundation, Italy | 258 | 2009-05-01 | 2025-02-11 |
Pulmonary Disease, Chronic Obstructive (6) · Bronchitis, Chronic (1) · Inflammation (1) · Lung Diseases (1) · Pneumonia (1) · Respiration Disorders (1) · Smoking (1)
Chronic Disease (7) · Disease Attributes (7) · Lung Diseases, Obstructive (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Tract Diseases (7) · Lung Diseases (6) · Infections (2) · Respiratory Tract Infections (2) · Behavior (1) · Bronchial Diseases (1) · Bronchitis (1) · Pulmonary Disease, Chronic Obstructive (1)
Formoterol Fumarate (4) · Ipratropium (2) · revefenacin (2) · Albuterol (1) · Atorvastatin (1) · Azithromycin (1) · Budesonide (1) · Dry Powder Inhalers (1) · Enoximone (1) · Fluticasone-Salmeterol Drug Combination (1) · Glycopyrrolate (1) · Levofloxacin (1) · Nebulizers and Vaporizers (1) · Prednisolone (1) · Roflumilast (1)
Chronic Obstructive Pulmonary Disease Trial Network, Denmark (2) · University of Tennessee Graduate School of Medicine (2) · AstraZeneca (1) · Central Denmark Region (1) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · Fadoi Foundation, Italy (1) · Medical University of Bialystok (1) · PARZIBUT Gilles (1) · Rijnstate Hospital (1) · University of Milan (1) · University of Oxford (1) · Wake Forest University Health Sciences (1)
Denmark (4) · United States (4) · Italy (3) · Argentina (1) · Canada (1) · Chile (1) · Colombia (1) · Malaysia (1) · Mexico (1) · Netherlands (1) · Peru (1) · Philippines (1) · Poland (1) · Romania (1) · Russia (1)
Francesco B Blasi, MD (1) · Gualberto GG Gussoni, MD, PhD (1) · Jill A Ohar, MD, FCCP (1) · Martin F Gude, PhD (1) · Mona Bafadhel, MBChB, PhD (1) · Peter Hallas, MD (1) · Simon Thorgaard-Rasmussen, MD (1) · Sune Laugesen, MD (1)
PMID 27585384, PMID 29579254, PMID 29763572, PMID 38273393, PMID 39165373, PMID 40898355, PMID 41340061, PMID 42548489
2019 (1)